Q2 2023 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2023-08-14 · accession 0001420506-23-001580
$1.67B
Reported value
48
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 43157M102 | — | HILLEVAX INC | $168.1M | 10.0% | 9,781,472 | Common | SOLE |
| 16961L106 | — | CHINOOK THERAPEUTICS INC | $167.0M | 9.97% | 4,345,559 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $144.8M | 8.65% | 10,109,279 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $129.3M | 7.72% | 10,871,803 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $116.3M | 6.94% | 990,260 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $112.8M | 6.74% | 4,360,107 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $82.8M | 4.94% | 8,684,232 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $77.6M | 4.64% | 3,708,838 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $62.2M | 3.72% | 2,944,349 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $58.2M | 3.47% | 1,164,405 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $35.7M | 2.13% | 2,167,222 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $34.2M | 2.04% | 1,988,876 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $32.3M | 1.93% | 1,787,527 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $30.7M | 1.83% | 2,985,757 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $29.1M | 1.74% | 3,238,859 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $29.1M | 1.74% | 655,000 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $25.5M | 1.52% | 1,414,823 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $22.9M | 1.37% | 854,484 | Common | SOLE |
| 88369M101 | — | THESEUS PHARMACEUTICALS INC | $21.0M | 1.25% | 2,248,194 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $20.5M | 1.23% | 857,338 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $19.7M | 1.17% | 746,479 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $18.3M | 1.09% | 899,700 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $17.8M | 1.06% | 1,501,383 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $17.5M | 1.05% | 1,028,013 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $17.1M | 1.02% | 994,858 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $17.0M | 1.01% | 830,983 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $16.6M | 0.99% | 2,142,855 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $16.4M | 0.98% | 6,881,090 | Common | SOLE |
| 61775R105 | MORFUSD | MORPHIC HLDG INC | $15.2M | 0.91% | 265,511 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $12.5M | 0.75% | 393,000 | Common | SOLE |
| 75615P103 | — | REATA PHARMACEUTICALS INC | $10.2M | 0.61% | 100,430 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $9.6M | 0.58% | 1,803,204 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $9.0M | 0.54% | 386,762 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $8.9M | 0.53% | 3,746,857 | Common | SOLE |
| G72800108 | PRTA | PROTHENA CORP PLC | $8.7M | 0.52% | 127,900 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $8.3M | 0.50% | 203,684 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $7.1M | 0.42% | 285,331 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $5.8M | 0.35% | 749,022 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $5.7M | 0.34% | 300,000 | Common | SOLE |
| 09609G100 | — | BLUEBIRD BIO INC | $5.6M | 0.34% | 1,709,907 | Common | SOLE |
| 24344T101 | DCPHEUR | DECIPHERA PHARMACEUTICALS IN | $5.2M | 0.31% | 370,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $4.8M | 0.29% | 881,173 | Common | SOLE |
| 39868T105 | 2JQ | GRITSTONE BIO INC | $4.7M | 0.28% | 2,401,714 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $3.6M | 0.22% | 780,000 | Common | SOLE |
| H0036K147 | ADCT | ADC THERAPEUTICS SA | $3.5M | 0.21% | 1,647,030 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $2.7M | 0.16% | 264,377 | Common | SOLE |
| 702712100 | — | PASSAGE BIO INC | $1.7M | 0.10% | 1,850,000 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $1.0M | 0.06% | 500,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.